InsidersTradesSigma
Explore the full insider trade history of GENEREX BIOTECHNOLOGY CORP, a publicly traded company based in United States. Shares trade on US US, under the supervision of SEC (Form 4). The latest transaction was reported on 16 February 2016 (Levée d'options). Among the most active insiders: Brusegard David. The full history is free.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
4 of 4 declarations
GENEREX BIOTECHNOLOGY CORP is a company focused on developing therapeutic solutions for the treatment of diabetes and other diseases. It is listed on NASDAQ under the symbol XNAS.